FDA Releases Draft Guidance On Closed-Loop Artificial Pancreas Devices
This article was originally published in The Gray Sheet
Executive Summary
Draft issued Dec. 1 emphasizes flexible clinical trial designs to support approval of glucose monitor/insulin pump combination devices that work together without the need for patient intervention.
You may also be interested in...
Artificial Pancreas Guidance Allows For More Flexibility In Trial Design
FDA’s final guidance on the design and clinical study of artificial pancreas systems broadens the study endpoints permissible for the devices, which aim to “close the loop” in the treatment of type 1 diabetes.
Regulatory News In Brief
FDA issues final guidance on IDE and PMA requirements for artificial pancreas devices. CDRH plans Office of Compliance reorganization. More regulatory news.
One Study Down, Three To Go On Animas’ First-Gen Artificial Pancreas Project
Following a successful feasibility study, the J&J unit still has multiple clinical milestones to hit before it can put its closed-loop diabetes treatment system up for market approval.